What's happening
Live detector signal
Generated 00:51 ET
KPTI — Karyopharm Therapeutics Inc is down 50.6%, at 0.02, on $278.8K traded, 0.66× float rotation. Score 74. Primary driver: 66.4% float rotation. Supply intelligence: squeeze-prone · 82.
Get alerts on $KPTI
Halts, resumptions, new filings, and updated reports — in your inbox within minutes of the event.
Free · one email per event, no digests or spam · unsubscribe anytime · joins real followers
Free float
—, refreshing
2026-10-08
Shares out
—, refreshing
latest detail
Market cap
—, refreshing
at ref price
Short interest
38.7%
2026-10-30
Float rotation
0.66×
latest snapshot
20d dollar vol
$4.1M
baseline
Gap quality
squeeze-prone · 82
live supply-pressure model
Supply factor
negative gap pressure
detector reason
Supply factor
heavy float rotation
detector reason
Supply factor
high short interest
detector reason
Supply factor
nano-cap supply profile
detector reason
This estimates whether a gap is clean, squeeze-prone, mixed, or supply-heavy using float, float rotation, short interest, market cap, split risk, and live volume. Registered resale/ATM exhaustion is a planned deeper parser layer.
2026-11-10 13:55 ETSignalKaryopharm Therapeutics Inc is down 50.6%, at 0.02, on $278.8K traded, 0.66× float rotation. Score 74. Primary driver: 66.4% float rotation. Supply intelligence: squeeze-prone · 82.
2026-11-038-KItem 1.01 — Entry into a material definitive agreement; Item 2.03 — Creation of a direct financial obligation +1 more SEC
2026-11-028-KItem 7.01 — Regulation FD disclosure; Item 9.01 — Financial statements and exhibits SEC
2026-09-188-KItem 3.03 — Material modification to rights of security holders; Item 5.03 — Amendments to charter or bylaws +1 more SEC
2026-09-03 13:00 ETFDA / ClinicalAdvanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight News
2026-08-04 16:51 ETOfferingINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI News
2026-06-14 06:30 ETFDA / ClinicalMenarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress News
2025-03-01 08:45 ETAnalyst RatingInternational Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month News
Latest detector signalscore 74